20/05/2025 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 1.8 million subscribed by a limited number of investors Download PDF Post navigationPreviousPrevious post:AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041Related PostsAB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041May 19, 2025AB Science reports a new publication in the scientific journal PLOS OneMay 15, 2025CNews – Interview of Alain MoussyMay 12, 2025Annual financial results as of 31 December, 2024May 12, 2025AB Science will present new data from masitinib clinical program in ALS in two presentations at the 2025 ENCALS Annual MeetingMay 5, 2025AB Science will publish its 2024 annual financial report on May 9, 2025May 1, 2025
AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041May 19, 2025
AB Science will present new data from masitinib clinical program in ALS in two presentations at the 2025 ENCALS Annual MeetingMay 5, 2025
